Drug
Visilizumab clinical trials
- studies test it
- 13
- open now
- 0
- in phase 3
- 5
- first study started
- 2001
How studies write it
Studies that test it under each name
Name
Studies by the year they started
12 studies that test it; most in 2002 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 3 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 10
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 4
Facet Biotech (8) · Stanford University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Abbott (1) · The First Affiliated Hospital of Soochow University (1) · Fred Hutchinson Cancer Center (1)
Studies
Open first, then newest update. How each study uses visilizumab is read from its arms, and is right about nine times in ten.
Testing it · 13
- PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AMLStatus unknownPhase 3The First Affiliated Hospital of Soochow UniversityNCT04722952Written as Visilizumab
- Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell TransplantationTerminatedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT00720629Written as Visilizumab
- Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent LymphomaCompletedPhase 1Stanford UniversityNCT00006009Written as visilizumab
- Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)TerminatedPhase 2AbbottNCT00307827Written as Visilizumab
- Research Study of Visilizumab for Treatment of Acute Graft Versus Host DiseaseCompletedPhase 1/2Facet BiotechNCT00032292Written as Visilizumab
- A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative ColitisTerminatedPhase 2/3Facet BiotechNCT00279422Written as visilizumab
- Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab StudyTerminatedPhase 2/3Facet BiotechNCT00279435Written as visilizumab
- Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative ColitisCompletedPhase 1/2Facet BiotechNCT00267306Written as Visilizumab
- Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's DiseaseCompletedPhase 2Facet BiotechNCT00267722Written as Visilizumab
- Visilizumab for Treatment of Perianal Fistulas in Crohn's DiseaseCompletedPhase 2Facet BiotechNCT00267709Written as Visilizumab
- Research Study in Patients With Severe Ulcerative ColitisCompletedPhase 2/3Facet BiotechNCT00032305Written as Visilizumab
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative ColitisWithdrawnPhase 3Facet BiotechNCT00502294Written as Visilizumab (HuM291; Nuvion®)
- Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host DiseaseStatus unknownPhase 2Fred Hutchinson Cancer CenterNCT00032279Written as Visilizumab
Codes
What other systems call visilizumab · ClinicalTrials.gg INT004449
- MeSH (NLM) C456519visilizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) H18SKU3289VISILIZUMABConfirmed FDA, NLM
- NCI Thesaurus C2229VisilizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C456519 | visilizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | H18SKU3289 | VISILIZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C2229 | Visilizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.